✦ LIBER ✦

Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer

✍ Scribed by Wolfgang Schuette; Sylke Nagel; Stefan Juergens; Ines Bork; Bettina Wollschlaeger; Steffen Schaedlich; Thomas Blankenburg

Book ID: 115076600
Publisher: CIG Media Group, LP.
Year: 2005
Tongue: English
Weight: 508 KB
Volume: 7
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2005.n.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-570 Phase II trial of biweekly irinote

P-570 Phase II trial of biweekly irinotecan (CPT-11) plus gemcitabine (GEM) combination in refractory or relapsed Small Cell Lung Cancer (SCLC)

✍ Castellano, Daniel; Ciruelos, Eva; García-Girón, Carlos; Lopez-Martin, Ana; Garr 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

P-572 A spanish multicentric phase II st

P-572 A spanish multicentric phase II study of gemcitabine — irinotecan in relapsing or refractory small cell lung cancer (SCLC)

✍ Domine, Manuel; Gomez, Ramon Garcia; Provencio, Mariano; Gonzalez Larriba, Jose 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Phase II study of weekly irinotecan and

Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer

✍ Naka, Nobuyuki; Kawahara, Masaaki; Okishio, Kyoichi; Hosoe, Shigeto; Ogawara, Mi 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Phase II study of irinotecan and carbopl

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer

✍ Hirose, Takashi; Horichi, Naoya; Ohmori, Tohru; Ogura, Keiichi; Hosaka, Takamich 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Phase II trial of irinotecan, cisplatin

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 87 KB 👁 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Paclitaxel and gemcitabine for refractor

Paclitaxel and gemcitabine for refractory or relapsed small cell lung cancer (SCLC). A multicentric phase II study

✍ M. Domine; J. Gonzalez Larriba; R. Garcia Gomez; S. Morales; D. Isla; C. Garcia 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 339 KB